Tovetumab References

Tovetumab
Monoclonal antibody
Type	?
Source	Human
Target	PDGFRA
Clinical data
ATC code	none;
Identifiers
CAS Number	1243266-04-7;
ChemSpider	none;
UNII	2XY62K75UV;
KEGG	D10411;
Chemical and physical data
Formula	C6400H9906N1726O2002S54
Molar mass	144792.97 g·mol−1

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer.^[1] It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer.^[2] Development was discontinued in 2013.^[3]^[4]

This drug was developed by MedImmune, LLC.^{[
citation needed]}

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
^ Liang M, Wang B, Schneider A, Vainshtein I, Roskos L (November 2020). "A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy". The AAPS Journal. 23 (1): 4. doi: 10.1208/s12248-020-00523-3. PMID 33210183. S2CID 227067803.
^ "Tovetumab". AdisInsight. Springer Nature Switzerland AG.
^ Williams R (January 2015). "Discontinued in 2013: oncology drugs". Expert Opinion on Investigational Drugs. 24 (1): 95–110. doi: 10.1517/13543784.2015.971154. PMID 25315907. S2CID 23390614.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.

[pmid33210183-2] Liang M, Wang B, Schneider A, Vainshtein I, Roskos L (November 2020). "A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy". The AAPS Journal. 23 (1): 4. doi: 10.1208/s12248-020-00523-3. PMID 33210183. S2CID 227067803.

[3] "Tovetumab". AdisInsight. Springer Nature Switzerland AG.

[pmid25315907-4] Williams R (January 2015). "Discontinued in 2013: oncology drugs". Expert Opinion on Investigational Drugs. 24 (1): 95–110. doi: 10.1517/13543784.2015.971154. PMID 25315907. S2CID 23390614.

[1]

[2]

[3]

[4]